AOL
MAIL
- You might also like:
- AOL Jobs,
- AOL Real Estate
- and More

Ticker

Advertisement Find a Broker - Visit the DailyFinance Broker Center

DJIA	12,454.83	-74.92	-0.60%
NASDAQ	2,837.53	-1.85	-0.07%
S&P 500	1,317.82	-2.86	-0.22%

Recent Quotes Watchlist My Portfolios

Add

$20.57 -$0.08 (-0.39%)

REAL-TIME: Last trade at 4:00 PM EDT on 05/25/12

Seattle Genetics, Inc.

NASDAQ:SGEN

+ Add to Portfolio
+ Add to Alerts

Related Resources

Celldex Targeted Drug Shrinks Breast Cancer

5/23/2012 by TheStreet.com

Seattle Genetics, Inc. Follows the Science, Taking on Rare Lymphoma No. 3

5/23/2012 by BioSpace

Seattle Genetics' ADCETRIS accepted for review by Health Canada

5/23/2012 by Theflyonthewall.com

Seattle Genetics Announces Health Canada Accepts ADCETRIS® New Drug Submission for Review

5/23/2012 by Business Wire

7 Stocks Surging on Big Volume

5/18/2012 by TheStreet.com

An Early Look at 2012 ASCO Biotech Cancer Stocks (DNDN, LLY, AMGN, ARIA, ARQL, ARRY, AVEO, BVTI, ABPI, BMY, CLDX, CYTR, CYCC, GALE, EXEL, GNBT, GHDX, IMGN, MYGN, NKTR, NLNK, ONXX, OPTR, PCYC, SGEN, SNSS, SNTA)

5/18/2012 by 24/7 Wall Street

ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update)

5/17/2012 by TheStreet.com

Seattle Genetics to Present ADCETRIS® and ASG-5ME Data at ASCO Annual Meeting

5/16/2012 by Business Wire

ASCO '12 Abstract Dump: Cancer Stocks in Focus

5/16/2012 by TheStreet.com

Seattle Genetics has a conference call hosted by JP Morgan

5/11/2012 by Theflyonthewall.com

Seattle Genetics to Present at Bank of America Merrill Lynch Health Care Conference

5/11/2012 by Business Wire

Taking An Early Look at 2012 ASCO Biotech/Cancer Stocks (DNDN, LLY, ARIA, ARRY, BVTI, ABPI, CLDX, CYTR, GALE, EXEL, GNBT, GHDX, IMGN, NKTR, NLNK, PCYC, SGEN)

5/10/2012 by 24/7 Wall Street

Seattle Genetics announces ADCETRIS interim trial data

5/10/2012 by Theflyonthewall.com

Seattle Genetics Announces Data from Investigator Trial of ADCETRIS™ in Relapsed Cutaneous T-Cell Lymphoma

5/10/2012 by Business Wire

Seattle Genetics shares should be bought on weakness, says RBC Capital

5/9/2012 by Theflyonthewall.com

Seattle Genetics price target lowered to $21 from $24 at Leerink

5/9/2012 by Theflyonthewall.com

Seattle Genetics Inc. (SGEN) Tops Q1 EPS by 1c

5/8/2012 by StreetInsider.com

Seattle Genetics sees FY12 ADCETRIS sales $140M-$150M

5/8/2012 by Theflyonthewall.com

Seattle Genetics reports Q1 EPS (11c), consensus (12c)

5/8/2012 by Theflyonthewall.com

Seattle Genetics Reports First Quarter 2012 Financial Results

5/8/2012 by Business Wire

5 Stocks Set to Soar on Bullish Earnings

5/7/2012 by TheStreet.com

Seattle Genetics shares should be bought ahead of ASCO, says RBC Capital

5/1/2012 by Theflyonthewall.com

Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2012 Financial Results on May 8, 2012

4/24/2012 by Business Wire

Biotech names with the highest probability of M&A activity at Goldman

4/23/2012 by Theflyonthewall.com

Seattle Genetics and Millennium to collaborate with Ventana on diagnostic test

4/12/2012 by Theflyonthewall.com

Seattle Genetics and Millennium to Collaborate with Ventana on Companion Diagnostic for ADCETRIS™ in CD30-Positive Malignancies

4/12/2012 by Business Wire

BofA/Merrill's biotech analyst holds an analyst/industry conference call

4/11/2012 by Theflyonthewall.com

Bullish on Biotechs

4/4/2012 by CNBC Video

Seattle Genetics shares should be bought on any weakness, says RBC Capital

4/4/2012 by Theflyonthewall.com

Seattle Genetics Demonstrates Continued Leadership in Antibody-Drug Conjugates at AACR

4/3/2012 by Business Wire

Seattle Genetics to Present at Needham Healthcare Conference

3/29/2012 by Business Wire

4 Biotech ETFs for a Healthy Portfolio

3/27/2012 by InvestorPlace

Seattle Genetics announces positive results from study of ADCETRIS

3/26/2012 by Theflyonthewall.com

Seattle Genetics Announces Pivotal ADCETRIS™ (Brentuximab Vedotin) Hodgkin Lymphoma Study Published in Journal of Clinical Oncology

3/26/2012 by Business Wire

Seattle Genetics Appoints Dr. Nancy Simonian to Board of Directors

3/21/2012 by Business Wire

Seattle Genetics should be bought on any near-term weakness, says RBC Capital

3/19/2012 by Theflyonthewall.com

Seattle Genetics management to meet with RBC Capital

3/9/2012 by Theflyonthewall.com

Seattle Genetics: A Cancer Niche Too Small

3/5/2012 by TheStreet.com

Cancer Treatments Evolve - Exelixis and Seattle Genetics Look to Lead

2/27/2012 by Marketwire

Seattle Genetics to Present at Upcoming Investor Conferences

2/23/2012 by Business Wire

See More Articles...

Get the latest SGEN stock information on the web. Get the latest stock quote and more - DailyFinance is your source for Seattle Genetics, Inc. stock price.

BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
Analyst Recommendations provided by Midnight Trader, Inc. Company Conference Calls provided by Wall Street Horizon.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions.

Notices & Terms: Confirm all data with your broker before trading.

Questions or Comments? Please give feedback here.

© 2012 AOL Inc. All Rights Reserved.

AOL@Money © 2012 AOL Inc. All Rights Reserved.

WEB105 / 31.251 ms